(Reuters) – Gilead Sciences Inc posted a 26% rise in quarterly revenue on Thursday, helped by sales of its antiviral drug, remdesivir, which is authorized to treat COVID-19 patients across the world.
Remdesivir brought in $1.9 billion in the fourth quarter ended Dec. 31, above analysts’ estimates of $1.34 billion, according to Refinitiv IBES data.
(Reporting by Vishwadha Chander in Bengaluru; Editing by Anil D’Silva)
